NYSE$CTEV
Claritev Corp · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
MultiPlan's financial performance demonstrated strength, with revenue and Adjusted EBITDA in-line with expectations, and progress made on the Extend growth strategy.
MultiPlan reported Q1 2021 revenues of $254.9 million and net income of $45.9 million. The company processed approximately $29 billion in claims during the quarter, identifying potential medical cost savings of approximately $4.9 billion. Full year 2021 revenue guidance is $1.04 billion to $1.10 billion.
- Q1 2021 revenues reached $254.9 million, a 1.1% increase over Q1 2020.
- Q1 2021 net income was $45.9 million, compared to a net loss in Q1 2020.
- Q1 2021 Adjusted EBITDA totaled $191.1 million.
- The company completed the acquisition of Discovery Health Partners in February.
Headline financials
Revenue & EPS history
Multiplan · Revenue · Quarterly
$255M
Forward guidance
The Company anticipates Q2 2021 revenues between $260 million and $275 million with Adjusted EBITDA between $185 million and $200 million. For the 2021 year, the Company is providing revenue guidance between $1.04 and $1.10 billion and Adjusted EBITDA between $750 and $790 million.
Tailwinds
- Full Year 2021 Revenue guidance of $1.04 billion to $1.10 billion
- Full Year 2021 Adjusted EBITDA guidance of $750 million to $790 million
- Q2 2021 Revenue guidance of $260 million to $275 million
- Q2 2021 Adjusted EBITDA guidance of $185 million to $200 million
Headwinds
- Estimated COVID-related revenue impact of between $18 million and $22 million per quarter
- Estimated COVID-related Adjusted EBITDA impact of between $16 million and $20 million per quarter
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
-6.5%
Avg return
Earnings day
-5.1%
Avg return
5 days after
-3.8%
Avg return
30 days after
36%
9 / 25 earnings
Positive
+20.8%
Q1 2021
Best reaction
-32.8%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -8.8% | +7.7% | -2.6% | |
| Q4 2025 | -31.8% | -42.0% | -31.4% | |
| Q3 2025 | +11.8% | -5.4% | -45.2% | |
| Q1 2025 | +4.2% | +7.5% | +95.1% | |
| Q4 2024 | -32.8% | -28.1% | -24.8% | |
| Q3 2024 | -6.5% | -3.4% | -22.6% | |
| Q2 2024 | -23.9% | -10.2% | -47.8% | |
| Q1 2024 | +10.9% | -1.5% | -36.6% | |
| Q4 2023 | -0.9% | -13.4% | -27.6% | |
| Q3 2023 | -6.5% | -9.7% | -14.3% | |
| Q2 2023 | -8.9% | -14.0% | -17.8% | |
| Q1 2023 | -5.4% | +21.0% | +97.6% | |
| Q4 2022 | -10.2% | +10.0% | +6.0% | |
| Q3 2022 | -27.8% | -18.3% | -31.1% | |
| Q2 2022 | -12.4% | -13.4% | -33.1% | |
| Q1 2022 | +1.0% | +18.4% | +27.4% | |
| Q4 2021 | -8.0% | -18.9% | -14.4% | |
| Q3 2021 | +0.2% | -11.0% | -4.3% | |
| Q2 2021 | -6.2% | -10.5% | -20.6% | |
| Q1 2021 | +20.8% | +27.0% | +45.5% | |
| Q2 2020 | +0.5% | -0.2% | +1.9% | |
| Q4 2020 | -18.6% | -20.3% | -19.7% | |
| Q3 2020 | -4.6% | +0.7% | +20.8% | |
| Q1 2020 | +0.5% | +0.7% | +2.3% | |
| Q4 2019 | +0.5% | +0.7% | +2.3% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro